We showed that the MMC-treated IL-15:IL-15Rα-B16F10-OVA vaccine inhibited the tumor growth of B16F10-OVA by enhancing splenic central memory CD8+ T cells, tumor-infiltrating NK cells, and tumor-infiltrating effector memory CD4+ and CD8+ T cells. Here, IL15RA is linked to neoplasm.